ARCHIVES

Moertel Criticizes Janssen Over Levamisole Price, Delivers Final Report On Intergroup Adjuvant Trial

This article is from The Cancer Letter archive.

Vol. 18 No. 24 | June 12, 1992

Download PDF Visit The Full Archive

Related Articles

Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone

April 10, 1987

FDA IND Approval Of New Cancer Drug Is First Based On Phase 1 Clinical Trials In Europe

December 5, 1986

NCI To Place 20% Cap On Grant Renewal Increases.

May 25, 2001

Duke Insiders Allege Intimidation By Administration

July 23, 2010

Researchers Find Two Types Of MCL Drug Resistance

August 29, 2014

ODAC Okays Photofrin for Obstructive Esophageal Cancer

September 23, 1994